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Abstract 
Objective. To assess clinical features, diagnostic procedures, therapies and outcomes in patients with clinically non-
functioning pituitary adenomas (NFPAs) surgically treated over the last four decades. 
Design and methods. A multicenter retrospective study in NFPA patients periodically followed up in specialized 
neuroendocrinology units who underwent surgery in the period 1977–2015 was performed. 
Results. A total of 131 patients were studied [66 women (50.4%); mean age 52.6 ± 14.8 years (range, 15–82)]. 
Median diameter of the adenoma was 2.6 cm (interquartile range, 2.0–3.1). The most frequently type of surgery used 
was endoscopic endonasal surgery (58.5%) followed by microscopic transsphenoidal surgery (37.4%). Radiation 
therapy was used in 19 patients (14.5%). Ki-67 labeling index performed in 54 patients was ≤ 2% in 70% samples. 
After a median follow-up time of 57 months (25 to 128 months), tumor diameter significantly decreased to 0.9 cm 
(0–1.8 cm), p < 0.001. Multivariant analysis showed that endoscopic endonasal surgery (HR 2.74, 1.06–6.87, 
p = 0.036) and radiotherapy (HR 0.04, 0.02–0.65, p = 0.024) behaved as positive and negative predictors, 
respectively, of tumor absence in the follow-up. Endoscopic endonasal surgery (HR 6.71, 1.45–31.05, p = 0.015) was 
the only positive predictor for complete cure in the follow-up. 
Conclusion. NFPAs surgically treated in Spain are usually macroadenomas diagnosed around the sixth decade of life 
with no sex predilection. Type of surgery is associated with clinical outcome. Endoscopic endonasal surgery behaves 
as a positive predictor for the absence of tumor imaging and complete cure in the follow up. 
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1. Introduction 
Today, pituitary adenoma (PA) is the third leading cause of intracranial neoplasia, following to 
meningioma and glioma [1], [2], [3], [4]. According to some surveys, its incidence has almost doubled 
over a period of 30 years, from 6 to 11 cases per million inhabitants/year [5], with a clinical prevalence 
around 1 case per 1000 inhabitants in recent studies [6]. The prevalence of PA in imaging studies is 
around 22.5%, with wide range (1–40%); while in autopsy studies is 14.4% (range 1–35%) [1]. 
 
PA can be functioning and nonfunctioning, according to the presence or absence of hormonal 
hypersecretion. The main types of PA are clinically non-functioning pituitary adenomas (NFPAs), 
prolactinomas, growth hormone (GH) secreting adenomas or somatotropinomas and corticotropin 
(ACTH) secreting adenomas or corticotropinomas. The frequency of the different types of PA is different 
and varies with age. While prolactinomas are the most common PA in young patients (2nd-4th decade of 
life), from age 40, the most prevalent are NFPAs [7]. 
 
NFPAs constitute about a third of all PA and its incidence has been estimated at 1.79/100,000 
inhabitants/year [8]. Its prevalence is around 26–90 cases per million and constitute 50% of pituitary 
tumors in large surgical series [8], [9]. In clinical series its prevalence is much greater around 400 per 
million [6]. 
 
NFPAs are the pituitary macroadenomas (≥ 1 cm) more frequent in adults and include primarily 
gonadotropinomas, which produce, although most of them do not secrete, gonadotropins or their subunits 
(mainly subunit alpha) followed by null cell adenomas, and finally other silent PA, such as 
corticotropinomas, somatotropinomas, and prolactinoma. Depending on the size, these tumors may be 
symptomatic or not. Macro-NFPAs are accompanied by considerable morbidity, usually associated with 
tumor mass effect causing neuro-ophthalmological symptoms and pituitary hormonal failure. On the 
contrary, micro-NFPAs (< 1 cm) are usually asymptomatic incidental findings on imaging studies. 
Treatment of choice is transsphenoidal surgery in symptomatic cases with the use or not of adjuvant 
radiotherapy in the case of persistent or recurrent disease, and periodic observation in asymptomatic 
tumors [10], [11], [12], [13], [14]. 
 
NFPAs series published to date in our country are scarce and have been usually performed in a small 
number (~ 30–50) of patients from a single hospital and with a short follow-up [15], [16], [17]. On the 
other hand, efficacy and surgical outcomes of the different surgical techniques in these tumors have not 
been clearly conclusive. In the present study we retrospectively reviewed the clinical characteristics, 
treatments used, pathological findings and clinical outcome of a large cohort of patients with NFPAs 
surgically treated in the last four decades in three Spanish tertiary hospitals. The main objectives were to 
study the relationship between different surgical techniques (microscopic and endoscopic) with absence 
of tumor and complete cure (absence of tumor and adenohypophysis normofunction) in the last medical 
visit. 
  
2. Patients and methods 
2.1. Patients 
A retrospective multicenter study of NFPAs underwent surgery between 1977 and 2015 in the 
Endocrinology department of three Spanish hospitals (Hospital Universitario Ramón y Cajal, Madrid; 
Complejo Hospitalario Universitario de A Coruña, A Coruña; and Hospital Universitario de Bellvitge, 
Barcelona) was performed. All registered cases of NFPA in each Endocrinology department during the 
study period were analyzed and all clinical records of the patients who underwent surgery were reviewed. 
 
Inclusion criteria were the histological demonstration of the tumor and the absence of clinical 
symptoms compatible with pituitary hyperfunction. For homogeneity, MEN 1 patients (n = 2) were 
excluded from the study. Patient percent distribution according to different hospitals included was: 
Hospital Ramón y Cajal, Madrid, n = 54 (41.2%); Hospital Universitario A Coruña, n = 42 (32.1%); and 
Hospital de Bellvitge, n = 35 (26.7%). Median follow-up was 57 months (interquartile range, 25 to 
128 months). 
2.2. Methods 
In every patient the following clinical parameters were recorded: age at diagnosis, personal and family 
history, drugs at the time of diagnosis, association or not with multiple endocrine neoplasia, main 
complaint at consultation, neuro-ophthalmological and endocrinological signs and symptoms and serum 
baseline hormonal determinations (PRL, GH, IGF-1, ACTH, cortisol, TSH, free T4, FSH, LH, estradiol 
in women and testosterone in men). The presence of hypopituitarism (partial or complete), number of 
axes involved, the presence of diabetes insipidus, and hyperprolactinemia was registered. Imaging study 
at diagnosis and the degree of visual impairment were also evaluated. 
 
Date of surgery, type and surgery technique, and surgical complications were recorded. 
Histopathological and immunohistochemical study of NFPAs was investigated. Lastly, after surgery, each 
patient was assessed on his/her last clinical visit analyzing clinical and laboratory data, the need of 
medical therapy and/or radiotherapy, tumor persistence/recurrence or clinical cure (absence of pituitary 
tumor in imaging study and normal pituitary function). 
2.3. Statistical analysis 
For quantitative variables, results are expressed as mean ± SD for normally distributed data, (age) and 
as median (interquartile range) for nonparametric data (time of follow-up and maximal tumor diameter). 
Adjustment to normal distribution was tested by the Kolmogorov test. Categorical variables are described 
as percentages. For comparisons of means between two groups of patients the Student t-test was used for 
normally distributed data (age), and the Mann-Whitney test to compare the medians of two different 
groups of patients (comparison of maximal tumor diameter in patients with and without hypopituitarism 
both before and after surgery). Willcoxon test was used to compare the medians for nonparametric data in 
the same group of patients (comparison of maximal tumor diameter at diagnosis and at last clinical visit). 
For categorical comparisons the χ2 test (evaluation of sex, age groups at diagnosis, persistence of tumor at 
last visit, tumor size group, Ki 67 value group, hyperprolactinemia, complete and partial hypopituitarism, 
and visual field alteration). Bonferroni correction to the α level was applied when tests with multiple 
comparisons were performed. Unadjusted and multivariate Cox regression were used to assess the effect 
of different qualitative variables (sex, age, maximal tumor diameter, suprasellar extension, cavernous 
sinus invasion, type of surgery (microscopic or endoscopic), and radiotherapy) on the absence of tumor 
and on magnetic resonance imaging (MRI) and complete cure at the last clinical visit. Hazard ratios (HR) 
and their 95% confidence intervals were calculated. Differences were considered significant when 
p < 0.05.  
3. Results 
3.1. Clinical features 
A group of 131 patients [66 women (50.4%); mean age 52.6 ± 14.8 years (range, 15–82)] was studied. 
Most patients (n = 69; 52.7%) were diagnosed at the age of 40–60 years. Only 3% (n = 4) of patients had 
an age lower than or equal to 25 years diagnosis while in 25.9% (n = 34) age at diagnosis was greater than 
or equal to 65 years. No significant differences in the distribution of patients according to sex and age at 
diagnosis were found (Fig. 1). 
 
 
 
Fig. 1. Percent distribution of 131 patients with NFPA who underwent surgery according to sex and age at diagnosis. 
In most patients (n = 103; 78.6%) the tumor was symptomatic, while the rest was an incidental finding 
in imaging study. The main complaint at initial visit was headache (n = 37) that appeared in nearly a third 
of patients (28.2%), followed by alterations in the visual field in 17 patients (13%), mainly as bitemporal 
hemianopsia, and decreased visual acuity in 12 patients (9.1%). Only 2 patients (1.5%) were diagnosed 
after a pituitary apoplexy. After the first clinical evaluation, neuro-ophthalmological symptoms were 
more frequent than endocrine ones (67.2% vs. 31.3%); being visual disturbances and, among them, visual 
field defects, the main symptoms (55.7%). Erectile dysfunction, decreased libido (6.9%), and asthenia 
(6.9%) in men (8.4%), and menstrual disorders (6.8%) in women, were the most frequent endocrine 
symptoms. 
3.2. Hormonal study 
Pituitary hormonal function was registered in 104 patients (79.4%). Of these, 8 patients (7.7%) had a 
complete anterior hypopituitarism, while hypopituitarism was partial in 47 patients (45.2%). Most 
patients with partial hypopituitarism showed deficiency in one axis (n = 20; 19.2%), followed by 3-axis 
deficiency (n = 14; 13.5%) and 2-axis deficiency (n = 13; 12.5%). The most frequently affected hormonal 
axis was gonadal (n = 43; 41.3%). 
  
Hypopituitarism was more common in men than in women (31.7% vs 21.1%; p = 0.005; χ2test). Men 
had a higher prevalence of central hypogonadism (26.9% vs 14.4%; p = 0.002; χ2test) and secondary 
hypothyroidism (18.3% vs 9.6%; p = 0.02; test), while women showed a higher prevalence of 
hyperprolactinemia (25% vs 9.6%; p = 0.003; χ2 test). 
 
There was a relationship between pituitary function and tumor size at diagnosis. Patients with 
hypopituitarism showed a tumor size significantly greater than that found in patients without 
hypopituitarism [2.9 cm (2.5–3.3 cm) vs 2.2 cm (1.9–3.0 cm); p = 0.003; Mann-Whitney test]. 
3.3. Imaging studies 
Most tumors (92.6%) were diagnosed with MRI and the rest by computed tomography (CT) scan 
brain. 97.5% of cases were macroadenomas. 17 of them (13.1%) were giant adenomas (diameter ≥ 4 cm). 
86.4% of tumors showed suprasellar extension; chiasmal compression occurred in 73.7% of patients. The 
invasion of the cavernous sinus was slightly lower (71.6%). The distribution of tumors according to the 
Knosp grading scale was as follows: grade 1 (8.3%); grade 2 (27.5%), grade 3 (21.1%), and grade 4 
(14.7%). In 16.5% of cases, the invasion of the cavernous sinus was bilateral. The presence of 
hydrocephalus was unusual (0.9%). 
 
Median maximum diameter of the adenoma was 2.6 cm (interquartile range, 2.0 to 3.1 cm). No 
significant differences in the maximum diameter of adenoma between men and women [2.8 cm (2.2 to 
3.2) vs 2.4 cm (2.0–3.0) were found; ns] neither do among the different age groups analyzed. 
3.4. Treatment and histopathologic results 
Type of surgery was recorded in 123 patients. The most frequently used was endoscopic endonasal 
surgery (n = 72; 58.5%) followed by microscopic transsphenoidal (n = 46; 37.4%). Transfrontal pituitary 
surgery was uncommonly performed (n = 5; 4.1%). 
 
The presence of hypopituitarism could be evaluated before and after surgery in 97 patients. Total 
hypopituitarism was similar after surgery (8.2% vs 9.3%, ns) whereas partial hypopituitarism increased 
significantly (46.4% vs 53.6%, p = 0.001; χ2 test). On the other hand, visual field examination was 
evaluated before and after surgery in 109 patients. In this case, the percentage of patients with alterations 
in the visual fields decreased after surgery (53.2% vs 19.3%, p = 0.027; test) (Table 1). 
Table 1. Percent distribution of tumors according to the presence of positivity in 
immunohistochemical staining for various anterior pituitary hormones (n = 123) 
Hormone Number of patients Percentage (%) 
   
LH 22 17.6 
FSH 21 16.8 
ACTH 11 8.8 
GH 8 6.8 
PRL 7 5.6 
TSH 4 3.2 
Negative 46 37.6 
   
 
  
There was also a relationship between tumor size at diagnosis and pituitary function after surgery. 
Patients with hypopituitarism after surgery showed a tumor size significantly greater than that found in 
patients without hypopituitarism [2.8 cm (2.2–3.3 cm) vs 2.2 cm (1.9–3.1 cm); p = 0.021; Mann-Whitney 
test]. 
 
Nineteen patients (14.5%) required a second surgery that was mainly due to persistence/recurrence or 
worsening of visual disturbances (n = 10, 7.6%). The mean time between the first and second surgeries 
was 46.8 ± 47.4 months (range, 2–156 months). 
 
The most common surgical complication was transient diabetes insipidus (n = 11; 8.4%), followed by 
cerebrospinal fluid leak (n = 8; 6.1%), and permanent diabetes insipidus (n = 5; 3.8%). Surgical mortality 
was 0.8% (n = 1). 
 
Nineteen (14.5%) were treated with radiotherapy. Twelve patients (9.2%) were treated with medical 
therapy after surgery. Indications for medical therapy were adenoma persistence (n = 7) or progression 
(n = 1), visual disturbances (n = 5) and headaches (n = 3). The drugs used were bromocriptine (n = 4), 
cabergoline (n = 4) and octreotide LAR (n = 3). 
 
Immunohistochemical study for anterior pituitary hormones was performed in 123 tumor samples. In 
47 patients (38.2%) immunohistochemical staining was negative. Hormones most frequently detected 
were gonadotropins, followed ACTH and GH (Table 2). 
Table 2. Clinical data of the patients at diagnosis and at last clinical visit. 
 
Basal Last visit 
   
Maximal tumor diameter (cm) 
(n = 131) 
2.6 (2.0–3.1) 0.9 (0–1.8)* 
Hypopituitarism 
(n = 97) 
 Total hypopituitarism (%) 8.2 9.3 
 Partial (%) 46.4 53.6* 
Visual field examination 
(n = 109) 
 Abnormal (%) 53.2 19.3 
   
 
Note: Figures indicate the percentage of patients (%) and/or the median (interquartile range). Willcoxon test for comparison of 
maximal tumor diameter and χ2 test for comparison of percentages of hypopituitarism and visual field examination presurgery and at 
last visit. 
* Level of significance for multiple comparisons was adjusted using the Bonferroni correction to alpha: p = 0.0125. 
Immunohistochemical study for Ki-67 was performed in 54 patients (≤ 2% in 38, 3% in 11 and ≥ 5% 
in 5 patients) (Fig. 2). Tumors with Ki-67 index ≥ 3% were significantly associated with giant adenomas 
(p = 0.019; χ2 test). 
  
 
 
 
Fig. 2. Percent distribution of tumors according to Ki-67 index value (n = 54). 
3.5. Clinical follow-up 
After a median follow-up of 57 months (25 to 128 months) maximal tumor diameter significantly 
decreased from 2.6 cm (2 to 3.1 cm) to 0.9 cm (0 to 1.8 cm), (p < 0.001, Willcoxon test). At the end of 
follow-up, 20 out of 120 patients (16.7%) had complete hypopituitarism and 49 patients (40.8%) partial 
hypopituitarism. The most frequently affected hormonal axis was gonadal (n = 55; 45.8%), followed by 
thyroid (n = 50, 41.7%) and adrenal (n = 42, 35%) axes. 
 
Visual field evaluation was abnormal in 24 out of 119 patients (20.2%). The main visual field 
abnormality was unilateral temporal hemianopia (n = 6, 5%), followed by bitemporal hemianopia (n = 5, 
5%) and bitemporal quadrantanopsia (n = 5, 5%). Although those patients who presented alterations in 
the visual field showed a greater tumor size at diagnosis than those who did not, these differences were 
not statistically significant [3.0 cm (2.1–3.5 cm) vs 2.5 cm (2.0–3.0 cm); p = 0.075]. 
 
Pituitary MRI in the last clinical visit was conducted in 112 patients and showed persistence of the 
tumor in most patients (n = 73, 65.2%) and absence in the rest (n = 39, 34.8%). There were no significant 
differences between these groups in relation to sex but there were in relation to age group at diagnosis 
(p = 0.03; χ2 test). Young patients (< 40 years) had a prevalence of tumor persistence ~ 6 times higher 
than older patients (≥ 40 years) (p = 0.03; χ2 test). Preoperative tumor size was similar in patients with 
and without tumor image in the last MRI [2.5 cm (2.0–3.6 cm) vs 2.7 cm (2.0–3.0 cm); ns]. The 
percentage of patients with persistent tumor in the last MRI was 61.8%, 70.4% and 80% for those who 
underwent endoscopic endonasal surgery, microscopic transsphenoidal and transfrontal surgery, 
respectively. 
 
At the end of the study, complete cure, defined as no tumor in the last pituitary MRI and normal 
pituitary function, was achieved in only 19 (17%) of the 112 patients who could be evaluated. Those 
patients who met adenoma cure criteria showed a significantly lower preoperative tumor size than those 
that were not cured [2.0 cm (1.6–2.7 cm) vs 2.7 cm (2.1–3.6 cm); p = 0.011; Mann-Whitney test]. 
 
In the univariate Cox regression analysis only endoscopic endonasal surgery (HR 3.60, 95% CI, 1.64–
7.88, p = 0.001) and radiotherapy (HR 0.09, 0.01–0.67, p = 0.019) behaved as positive and negative 
predictors, respectively, for the absence of tumor in the last MRI. In the multivariate analysis, both 
variables, endoscopic endonasal surgery (HR 2.74, 1.06–6.87, p = 0.036) and radiotherapy (HR 0.04, 
0.02–0.65, p = 0.024) also behaved as positive and negative predictors, respectively, of tumor absence in 
the follow-up (Fig. 3). 
  
 
 
 
Fig. 3. Unadjusted and adjusted hazard ratios (HR with 95% confidence interval, CI) for tumor absence in the last clinical visit in 
NFPA patients underwent surgery classified according to several clinical variables. 
In relation to complete cure rate, the univariate Cox regression analysis showed that endoscopic 
endonasal surgery (HR 6.84, 2.13–21.88, p = 0.001) and maximal diameter tumor (HR 0,45, 0.21–0.95, 
p = 0.035) were positive and negative predictors, respectively. In the multivariate analysis, endoscopic 
endonasal surgery (HR 6.56, 1.76–24.5, p = 0.005) behaved as the only positive predictor for complete 
cure in the follow-up, while maximal diameter tumor (HR 0.94, 0.89–0.99, p = 0.041) was the only 
negative predictor (Fig. 4). 
  
 
 
 
Fig. 4. Unadjusted and adjusted hazard ratios (HR with 95% confidence interval, CI) for complete cure in the last clinical visit in 
NFPA patients underwent surgery classified according to several clinical variables. 
4. Discussion 
The present study shows that surgical treated NFPAs mostly are pituitary macroadenomas starting 
symptomatically (headache and/or visual disturbances) in the sixth decade of life associated with 
hormone deficiencies in about half of patients. Although surgery controls tumor growth and improves 
visual disturbances, complete cure is unusual. Type of surgery is related to the disappearance of the 
adenoma and complete cure, being endoscopic endonasal surgery the main positive predictor for these 
clinical outcomes. 
 
Our study suggests that symptomatic NFPAs are diagnosed between 50 and 55 years without sex 
predilection. These data differ slightly from other series from our country where age was slightly lower 
(fifth decade) and with a slight predilection for females, from 1.1 to 1.4 (15, 16). These differences might 
be explained by the different age in the analyzed cohorts. Some studies suggest that there is a sexual 
dimorphism in NFPAs in relation to the age at diagnosis [7]. It has been reported that before the fourth 
decade, NFPAs are more common in women, while from that age, males are predominant. Our population 
confirms this observation showing a slight predominance in females in patients < 40 years and in males in 
patients over 60 years; however, between 40 and 60 years, the prevalence was similar in both sexes (Fig. 
1). 
 
NFPA may occur in the context of a MEN1, although it is rare (< 5%) [18]. Our study shows that the 
prevalence of MEN1 in NFPAs underwent surgery is very low (1.5%). 
  
The most common (50–60%) form of clinical presentation of NFP macroadenomas are symptoms 
resulting from increased intracranial pressure, in the form of headaches and/or visual disturbances [11]. 
According to some recent surgical and non-surgical series, almost half of the NFPAs are incidental [19]. 
In our series these percentages were different (78% of the patients were symptomatic) probably due to the 
intrinsic characteristics of the cohort, since all our patients underwent surgery. 
 
Although uncommon, endocrine symptoms recorded in our study were mainly related with 
gonadotropin deficiency, which is one of the most frequent hormone deficiency reported in these patients 
[15], [16], [19], [20]. The prevalence of hypopituitarism, partial or complete, at diagnosis was similar 
(~ 50%) to that described in other recently published series from a single hospital [19], [20]. 
 
The diagnosis of NFPA is performed by imaging tests, mainly MRI, which is the imaging test of 
choice [21]. In the surgical and nonsurgical series, the NFPA mean diameter is ~ 2 cm [19]; slightly lower 
than found in our series (mean 2.8 ± 1.1 cm). This is probably due to the fact that in our study only 
patients who underwent surgery and, therefore with larger tumors, were evaluated. In our patients 
suprasellar extension of the adenoma was more frequent than the invasion of the cavernous sinus (85% 
vs. 73%), which implies a greater likelihood of compression of the optic pathways. 
 
Both endoscopic endonasal and microscopic transsphenoidal approaches are recommended for 
symptom relief in patients with NFPAs [22]. Endoscopic endonasal surgery allows better visualization of 
areas of difficult access and larger tumor resections, and according some authors, it offers better surgical 
outcomes and lower complication rate [23], [24], [25], [26]. In our series remission rate ranged from 20% 
for transfrontal surgery to 36% for endoscopic endonasal surgery. These differences could be explained at 
least partly by the inherent characteristics of adenoma (size and invasiveness) at the time of the diagnosis. 
In our series, endoscopic endonasal surgery was associated to a lower likelihood of tumor persistence 
during follow-up compared with other surgical techniques, and behaved as an independent positive 
predictor of long-term tumor absence and complete cure. These data, together with those reported in the 
literature, would support the use of endoscopic technique in the surgical management of NFPAs. 
 
Postsurgical stereotactic radiotherapy achieves tumor disease stability in most (89–90%) of the 
NFPAs; however, radiation therapy has been associated with a high percentage of new hormonal 
deficiencies (20–30%) and, in some cases (1–13%), new visual disturbances [11]. In our study, 
hypopituitarism was slightly higher, probably because we consider the different radiotherapy techniques 
(stereotactic and conventional) as a whole. Furthermore, combination therapy with surgery and 
radiotherapy was associated to a lower likelihood of tumor persistence in the follow-up compared to 
surgery alone. 
 
The predictive value of Ki-67 index in NFPAs is controversial [11]. Some studies [27], [28], although 
not all [29], have found Ki-67 values more elevated in young patients (< 30 years) compared to older 
patients (> 40 years). Others have directly compared the rate of tumor growth with Ki-67 index in NFPAs 
[30], [31] finding an inverse correlation between Ki-67 index and the doubling time of tumor size in 
recurrent NFPAs [30]. It has also been reported that a value of Ki-67 ≥ 2% predicts an increased risk of 
progression of the residual adenoma after surgery, indicating the need to shorten the interval of 
neuroimaging study after surgery [32]. However, more recent studies have failed to show this association 
[33]. In our study, the value of Ki-67 was low (≤ 2%) in the majority (~ 70%) of the patients and a high 
value (≥ 3%) was not associated with age, sex, suprasellar extension or chiasm compression and the need 
for second surgery for tumor recurrence; however, it was associated with the presence of giant adenoma. 
 
When we consider as cure criteria the absence of tumor and normal pituitary function, the percentage 
of cured patients was < 20%. This is an interesting finding showing that a high percentage of patients 
persist with hormonal dysfunctions which implies a lifelong monitoring. As reviewed by Romijn et al., 
almost all patients who are appropriately treated for pituitary tumors enter a chronic phase with control or 
cure of hormonal excess, adequate treatment of pituitary insufficiency and relief of mass effects. This 
phase is associated with improvement of initial signs and symptoms, but also with the persistent 
consequences of the initial disease and associated treatments, leading to a chronic post-treatment 
syndrome [34]. 
 
Among the strengths of our study are the large number of patients evaluated and prolonged 
observation period analyzed. The main limitations are those derived from the type study, retrospective 
and multicenter, which involved the lack of uniformity in the therapeutic offer (different neurosurgeons 
and diverse surgical techniques) between hospital centers, and the absence of variables in some patients, 
such as Ki67. 
 
In conclusion, this study shows that NFPA undergoing surgery is a sporadic and symptomatic 
pituitary macroadenoma associated to headache and visual disturbances, which is mainly diagnosed in the 
4–6th decade of life, with no clear sex predilection. Hypopituitarism (partial or complete) at diagnosis 
occurs in about half of patients, being more frequent in males. Endoscopic endonasal surgery seems to 
behave as a positive predictor for the absence of tumor imaging and complete cure in the follow up. 
Adjuvant radiation therapy is occasionally used while medical treatment is used in exceptional cases. The 
cell proliferation index Ki-67 is generally low (< 3%) and high value (≥ 3%) is associated with cavernous 
sinus invasion and giant adenomas. Although surgery improves visual symptoms, pituitary function does 
not improve with time. Complete cure (absence of pituitary tumor and normal pituitary function) is 
uncommon so it requires a long-term monitoring. 
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